StockNews.AI

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

StockNews.AI • 4 hours

PENGSKRAPT
High Materiality8/10

Information

BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi...

Original source

AI Summary

Boston Scientific is acquiring Penumbra for $14.5 billion, valuing shares at $374. An ongoing investigation raises concerns about the fairness of the acquisition process, which could influence investor confidence and market perception of BSX's growth strategy and governance practices.

Sentiment Rationale

Historically, acquisitions like this one typically result in increased market confidence in the acquiring company, as seen with other successful merges that expanded product lines and market reach.

Trading Thesis

Investors should consider BSX as a buy amidst Penumbra's acquisition implications.

Market-Moving

  • Potential scrutiny could affect BSX's share price.
  • Successful acquisition may enhance BSX's market position.
  • Fairness investigation may influence BSX's governance perception.
  • Investor sentiment could shift based on acquisition outcomes.

Key Facts

  • Penumbra to be acquired by Boston Scientific for $14.5 billion.
  • Concerns about fair process in Penumbra's acquisition are under investigation.
  • Transaction values Penumbra at $374 per share.
  • BSX's market position may strengthen with Penumbra's acquisition.
  • Shareholder value implications are being scrutinized in the deal.

Companies Mentioned

  • Boston Scientific Corporation (BSX): Acquisition of Penumbra may strengthen BSX's portfolio and market presence.
  • Penumbra, Inc. (PEN): Penumbra's acquisition is central to BSX's growth outlook and shareholder dynamics.

Corporate Developments

This news falls under Corporate Developments as it highlights a significant acquisition by BSX that could reshape its business strategy and market standing, influencing investor sentiment and stock performance.

Brodsky & Smith Shareholder Update: Investigations Announced for Multiple Companies

BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) — Brodsky & Smith alerts investors about ongoing investigations into several public companies following various merger agreements. Shareholders seeking to discuss these investigations can reach out to Jason Brodsky or Marc Ackerman at Brodsky & Smith, with no financial obligation involved.

Investigations Overview

Current investigations involve four companies: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Calavo Growers, Inc. (Nasdaq – CVGW), Penumbra, Inc. (NYSE – PEN), and FONAR Corporation (Nasdaq - FONR). The focus is on whether the boards of these companies adequately fulfilled their fiduciary duties to shareholders during the merger processes.

RAPT Therapeutics, Inc. (Nasdaq – RAPT)

  • Acquisition Details: RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 per share.
  • Valuation: The estimated total equity value of the deal is $2.2 billion.
  • Investigation Focus: The inquiry centers on whether the Board failed to pursue a fair process, raising concerns about the deal's value to shareholders.

For more information, visit Brodsky & Smith’s website.

Calavo Growers, Inc. (Nasdaq – CVGW)

  • Acquisition Details: Calavo will be acquired by Mission Produce, Inc. where shareholders will receive $27.00 per share.
  • Structure of Payment: This includes $14.85 in cash and 0.9790 shares of Mission for each Calavo share.
  • Enterprise Value: The total valuation for Calavo is approximately $430 million.
  • Ownership Breakdown: Post-transaction, Mission shareholders would hold 80.3% of the combined company, with Calavo shareholders owning 19.7%.

Further details are available at Brodsky & Smith’s website.

Penumbra, Inc. (NYSE – PEN)

  • Acquisition Details: Penumbra is set to be acquired by Boston Scientific Corporation (NYSE: BSX) in a mixed cash and stock transaction.
  • Valuation: The deal values Penumbra at $374 per share, equating to an enterprise value of approximately $14.5 billion.
  • Investigation Focus: This investigation questions whether the Penumbra Board upheld its fiduciary duties to ensure a fair process for shareholders.

More information can be found at Brodsky & Smith’s website.

FONAR Corporation (Nasdaq - FONR)

  • Acquisition Details: FONAR will be acquired in an all-cash transaction for $19.00 per common share.
  • Investigation Focus: This inquiry focuses on potential breaches of fiduciary duties by the FONAR Board during the acquisition process.

For additional details, visit Brodsky & Smith’s website.

Brodsky & Smith’s Commitment to Shareholders

Brodsky & Smith is a litigation law firm dedicated to representing investors in securities and class action lawsuits. The firm has been recognized by various courts across the country, serving as lead counsel in numerous class actions and recovering millions for clients.

For any inquiries regarding these investigations or assistance with shareholder rights, please contact Brodsky & Smith's legal team.

Related News